| |
| |
|
| Insider
Information: |
Spiegelman Daniel K |
| Relationship: |
Director |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
155,668 |
|
|
Indirect Shares
|
6,673 |
|
|
| Direct
Value |
$5,222,943 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
162,341 |
|
|
| Total
Value |
$5,222,943 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
CV Therapeutics Inc |
CVTX |
SVP, CFO |
2009-04-09 |
67,489 |
2009-04-09 |
6,673 |
Premium* |
|
|
Cascadian Therapeutics, Inc |
CASC |
Director |
2018-03-09 |
0 |
2009-12-04 |
0 |
Premium* |
|
|
Biomarin Pharmaceutical Inc |
BMRN |
EVP, Chief Financial O... |
2019-04-30 |
47,686 |
2012-05-29 |
0 |
Premium* |
|
|
Relypsa Inc |
RLYP |
Director |
2016-09-01 |
0 |
2015-06-04 |
0 |
Premium* |
|
|
Myriad Genetics Inc |
MYGN |
Director |
2023-06-02 |
40,493 |
2020-05-27 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| CVTX |
CV Therapeutics Inc |
Senior Vice President and CFO |
• – – |
2004-12-16 |
4 |
S |
$23.86 |
$178,954 |
D/D |
(7,500) |
19,988 |
|
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2005-08-26 |
4 |
S |
$26.24 |
$564,317 |
D/D |
(21,506) |
0 |
|
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2005-11-03 |
4 |
S |
$25.21 |
$668,065 |
D/D |
(26,500) |
0 |
|
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2007-12-21 |
4 |
S |
$10.00 |
$60,000 |
D/D |
(6,000) |
6,446 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2009-04-02 |
4 |
S |
$19.91 |
$2,807,887 |
D/D |
(141,029) |
73,439 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2013-02-20 |
4 |
S |
$1.96 |
$25,054 |
D/D |
(12,780) |
24,047 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2013-05-01 |
4 |
S |
$64.42 |
$1,803,897 |
D/D |
(28,000) |
33,000 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2013-07-10 |
4 |
S |
$1.72 |
$5,854 |
D/D |
(3,403) |
20,644 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2014-03-05 |
4 |
S |
$82.93 |
$995 |
D/D |
(12) |
68,748 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2014-05-02 |
4 |
S |
$58.02 |
$644 |
D/D |
(11) |
68,737 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2014-07-02 |
4 |
S |
$64.00 |
$142,656 |
D/D |
(2,229) |
70,905 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2014-08-01 |
4 |
S |
$61.76 |
$137,652 |
D/D |
(2,229) |
68,676 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2014-09-02 |
4 |
S |
$69.83 |
$1,117,314 |
D/D |
(16,000) |
68,676 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2014-09-03 |
4 |
S |
$69.70 |
$1,256 |
D/D |
(18) |
68,733 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2015-03-02 |
4 |
S |
$107.00 |
$1,658,500 |
D/D |
(15,500) |
68,676 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2015-05-18 |
4 |
S |
$124.77 |
$256,905 |
D/D |
(2,059) |
75,585 |
0 |
- |
|
| RLYP |
Relypsa Inc |
Director |
– • – |
2016-06-07 |
4 |
S |
$19.31 |
$19,562 |
D/D |
(1,013) |
1,237 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2016-11-09 |
4 |
S |
$90.61 |
$1,812,206 |
D/D |
(20,000) |
23,100 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
Senior Vice President and CFO |
• – – |
2004-12-16 |
4 |
OE |
$9.00 |
$67,500 |
D/D |
7,500 |
27,488 |
|
- |
|
| CVTX |
CV Therapeutics Inc |
Senior Vice President and CFO |
• – – |
2004-12-28 |
4 |
OE |
$9.00 |
$9,000 |
D/D |
1,000 |
20,988 |
|
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2005-11-03 |
4 |
OE |
$9.00 |
$13,500 |
D/D |
1,500 |
1,500 |
|
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2005-11-03 |
4 |
OE |
$9.25 |
$231,250 |
D/D |
25,000 |
25,000 |
|
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2006-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
121 |
937 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2006-12-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
8,226 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2007-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,732 |
11,884 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
